Alternative Data for RedHill Biopharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | N/A | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Employee Rating | 54 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,235 | Sign up | Sign up | Sign up |
| X Followers | 1,348 | Sign up | Sign up | Sign up |
| X Mentions | 1 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 33 | Sign up | Sign up | Sign up |
| Linkedin Employees | 45 | Sign up | Sign up | Sign up |
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
| Price | $0.88 |
| Target Price | Sign up |
| Volume | 8,415 |
| Market Cap | $4.6M |
| Year Range | $0.88 - $2.52 |
| Dividend Yield | 0% |
| PE Ratio | 0 |
| Analyst Rating | 0% buy |
| Industry | Drug Manufacturers |
In the news
RedHill Biopharma Says Full Sales And Operational Launch Of Talicia, Under Joint Commercialization Agreement Between Talicia And Cumberland Pharmaceuticals Has startedFebruary 24 - Benzinga |
|
 |
RedHill Biopharma announces development progress for RHB-102January 5 - Thefly.com |
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
Ebola Virus Competitive Landscape Report 2026: Comprehensive Insights About 18+ Companies and 20+ DrugsFebruary 18 - GlobeNewswire |
|
Tenosynovial Giant Cell Tumors Market to Show Significant Growth by 2034 as CSF1R-Targeted Therapies Drive the Next Wave | DelveInsightJanuary 19 - GlobeNewswire |
|
 |
What's Going On With Redhill Biopharma Stock On Tuesday?January 6 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 2M | 800,000 | 1.2M | -2.1M | -2.1M | -2.290 |
| Q1 '25 | 2M | 800,000 | 1.2M | -2.1M | -2.1M | -4.020 |
| Q4 '24 | 0 | 0 | 0 | 0 | 0 | -4.020 |
| Q3 '24 | 2.7M | 890,000 | 1.8M | -2.6M | -1.8M | 0.000 |
| Q2 '24 | 1.3M | 700,000 | 580,000 | -1.5M | -4M | -200.000 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about RedHill Biopharma (RDHL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - RedHill Biopharma
The Market Cap of RedHill Biopharma is $4.6M.
As of today, RedHill Biopharma's PE (Price to Earnings) ratio is 0.
Currently, the price of one share of RedHill Biopharma stock is $0.88.
The RDHL stock price chart above provides a comprehensive visual representation of RedHill Biopharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling RedHill Biopharma shares. Our platform offers an up-to-date RDHL stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, RedHill Biopharma (RDHL) does not offer dividends to its shareholders. Investors interested in RedHill Biopharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of RedHill Biopharma are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
